Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 193

1.

Response to Comment on "Type I CD20 Antibodies Recruit the B Cell Receptor for Complement-Dependent Lysis of Malignant B Cells".

Engelberts PJ, Breij ECW, Valerius T, Schuurman J, Parren PWHI, Beurskens FJ.

J Immunol. 2018 Apr 15;200(8):2517. doi: 10.4049/jimmunol.1800233. No abstract available.

PMID:
29632251
2.

Structures of C1-IgG1 provide insights into how danger pattern recognition activates complement.

Ugurlar D, Howes SC, de Kreuk BJ, Koning RI, de Jong RN, Beurskens FJ, Schuurman J, Koster AJ, Sharp TH, Parren PWHI, Gros P.

Science. 2018 Feb 16;359(6377):794-797. doi: 10.1126/science.aao4988.

PMID:
29449492
3.

Impact of Fc gamma receptor polymorphisms on efficacy and safety of daratumumab in relapsed/refractory multiple myeloma.

van de Donk NWCJ, Casneuf T, Di Cara A, Parren PW, Zweegman S, van Kessel B, Lokhorst HM, Usmani SZ, Lonial S, Richardson PG, Chiu C, Mutis T, Nijhof IS, Sasser AK.

Br J Haematol. 2018 Feb 7. doi: 10.1111/bjh.15122. [Epub ahead of print] No abstract available.

PMID:
29411874
4.

Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors.

Boshuizen J, Koopman LA, Krijgsman O, Shahrabi A, van den Heuvel EG, Ligtenberg MA, Vredevoogd DW, Kemper K, Kuilman T, Song JY, Pencheva N, Mortensen JT, Foppen MG, Rozeman EA, Blank CU, Janmaat ML, Satijn D, Breij ECW, Peeper DS, Parren PWHI.

Nat Med. 2018 Feb;24(2):203-212. doi: 10.1038/nm.4472. Epub 2018 Jan 15.

PMID:
29334371
5.

Celebrating Antibody Therapeutics.

Parren PWHI, Huston JS.

Protein Eng Des Sel. 2017 Sep 1;30(9):573. doi: 10.1093/protein/gzx053. No abstract available.

PMID:
29088433
6.

Cysteine-SILAC Mass Spectrometry Enabling the Identification and Quantitation of Scrambled Interchain Disulfide Bonds: Preservation of Native Heavy-Light Chain Pairing in Bispecific IgGs Generated by Controlled Fab-arm Exchange.

van den Bremer ETJ, Labrijn AF, van den Boogaard R, Priem P, Scheffler K, Melis JPM, Schuurman J, Parren PWHI, de Jong RN.

Anal Chem. 2017 Oct 17;89(20):10873-10882. doi: 10.1021/acs.analchem.7b02543. Epub 2017 Oct 2.

PMID:
28922593
7.

CD20-Specific Immunoligands Engaging NKG2D Enhance γδ T Cell-Mediated Lysis of Lymphoma Cells.

Peipp M, Wesch D, Oberg HH, Lutz S, Muskulus A, van de Winkel JGJ, Parren PWHI, Burger R, Humpe A, Kabelitz D, Gramatzki M, Kellner C.

Scand J Immunol. 2017 Oct;86(4):196-206. doi: 10.1111/sji.12581.

8.

Changes to International Nonproprietary Names for antibody therapeutics 2017 and beyond: of mice, men and more.

Parren PWHI, Carter PJ, Plückthun A.

MAbs. 2017 Aug/Sep;9(6):898-906. doi: 10.1080/19420862.2017.1341029. Epub 2017 Jun 16.

9.

Hexamerization-enhanced CD20 antibody mediates complement-dependent cytotoxicity in serum genetically deficient in C9.

Taylor RP, Lindorfer MA, Cook EM, Beurskens FJ, Schuurman J, Parren PWHI, Zent CS, VanDerMeid KR, Burack R, Mizuno M, Morgan BP.

Clin Immunol. 2017 Aug;181:24-28. doi: 10.1016/j.clim.2017.05.016. Epub 2017 May 31.

10.

Efficient Generation of Bispecific Murine Antibodies for Pre-Clinical Investigations in Syngeneic Rodent Models.

Labrijn AF, Meesters JI, Bunce M, Armstrong AA, Somani S, Nesspor TC, Chiu ML, Altintaş I, Verploegen S, Schuurman J, Parren PWHI.

Sci Rep. 2017 May 30;7(1):2476. doi: 10.1038/s41598-017-02823-9.

11.

Hinge-deleted IgG4 blocker therapy for acetylcholine receptor myasthenia gravis in rhesus monkeys.

Losen M, Labrijn AF, van Kranen-Mastenbroek VH, Janmaat ML, Haanstra KG, Beurskens FJ, Vink T, Jonker M, 't Hart BA, Mané-Damas M, Molenaar PC, Martinez-Martinez P, van der Esch E, Schuurman J, de Baets MH, Parren PWHI.

Sci Rep. 2017 Apr 20;7(1):992. doi: 10.1038/s41598-017-01019-5.

12.

Enhancing Accuracy in Molecular Weight Determination of Highly Heterogeneously Glycosylated Proteins by Native Tandem Mass Spectrometry.

Wang G, de Jong RN, van den Bremer ETJ, Parren PWHI, Heck AJR.

Anal Chem. 2017 May 2;89(9):4793-4797. doi: 10.1021/acs.analchem.6b05129. Epub 2017 Apr 13.

13.

Monoclonal Antibodies against Epidermal Growth Factor Receptor Acquire an Ability To Kill Tumor Cells through Complement Activation by Mutations That Selectively Facilitate the Hexamerization of IgG on Opsonized Cells.

Tammen A, Derer S, Schwanbeck R, Rösner T, Kretschmer A, Beurskens FJ, Schuurman J, Parren PW, Valerius T.

J Immunol. 2017 Feb 15;198(4):1585-1594. doi: 10.4049/jimmunol.1601268. Epub 2017 Jan 6.

14.

Hitting Ebola, to the power of two.

Labrijn AF, Parren PW.

Science. 2016 Oct 21;354(6310):284-285. No abstract available.

PMID:
27846516
15.

Type I CD20 Antibodies Recruit the B Cell Receptor for Complement-Dependent Lysis of Malignant B Cells.

Engelberts PJ, Voorhorst M, Schuurman J, van Meerten T, Bakker JM, Vink T, Mackus WJ, Breij EC, Derer S, Valerius T, van de Winkel JG, Parren PW, Beurskens FJ.

J Immunol. 2016 Dec 15;197(12):4829-4837. Epub 2016 Nov 2.

16.

Efficient Payload Delivery by a Bispecific Antibody-Drug Conjugate Targeting HER2 and CD63.

de Goeij BE, Vink T, Ten Napel H, Breij EC, Satijn D, Wubbolts R, Miao D, Parren PW.

Mol Cancer Ther. 2016 Nov;15(11):2688-2697. Epub 2016 Aug 24.

17.

ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer-Containing Antibody-Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies.

Flynn MJ, Zammarchi F, Tyrer PC, Akarca AU, Janghra N, Britten CE, Havenith CE, Levy JN, Tiberghien A, Masterson LA, Barry C, D'Hooge F, Marafioti T, Parren PW, Williams DG, Howard PW, van Berkel PH, Hartley JA.

Mol Cancer Ther. 2016 Nov;15(11):2709-2721. Epub 2016 Aug 17.

18.

Antibody Engineering & Therapeutics 2016: The Antibody Society's annual meeting, December 11-15, 2016, San Diego, CA.

Larrick JW, Alfenito MR, Scott JK, Parren PW, Burton DR, Bradbury AR, Lemere CA, Messer A, Huston JS, Carter PJ, Veldman T, Chester KA, Schuurman J, Adams GP, Reichert JM.

MAbs. 2016 Nov/Dec;8(8):1425-1434. Epub 2016 Aug 24.

19.

The Human CD38 Monoclonal Antibody Daratumumab Shows Antitumor Activity and Hampers Leukemia-Microenvironment Interactions in Chronic Lymphocytic Leukemia.

Matas-Céspedes A, Vidal-Crespo A, Rodriguez V, Villamor N, Delgado J, Giné E, Roca-Ho H, Menéndez P, Campo E, López-Guillermo A, Colomer D, Roué G, Wiestner A, Parren PW, Doshi P, van Bueren JL, Pérez-Galán P.

Clin Cancer Res. 2017 Mar 15;23(6):1493-1505. doi: 10.1158/1078-0432.CCR-15-2095. Epub 2016 Sep 16.

20.

A novel label-free cell-based assay technology using biolayer interferometry.

Verzijl D, Riedl T, Parren PWHI, Gerritsen AF.

Biosens Bioelectron. 2017 Jan 15;87:388-395. doi: 10.1016/j.bios.2016.08.095. Epub 2016 Aug 28.

21.

Antibodies That Efficiently Form Hexamers upon Antigen Binding Can Induce Complement-Dependent Cytotoxicity under Complement-Limiting Conditions.

Cook EM, Lindorfer MA, van der Horst H, Oostindie S, Beurskens FJ, Schuurman J, Zent CS, Burack R, Parren PW, Taylor RP.

J Immunol. 2016 Sep 1;197(5):1762-75. doi: 10.4049/jimmunol.1600648. Epub 2016 Jul 29.

22.

Molecular Basis of Assembly and Activation of Complement Component C1 in Complex with Immunoglobulin G1 and Antigen.

Wang G, de Jong RN, van den Bremer ET, Beurskens FJ, Labrijn AF, Ugurlar D, Gros P, Schuurman J, Parren PW, Heck AJ.

Mol Cell. 2016 Jul 7;63(1):135-45. doi: 10.1016/j.molcel.2016.05.016. Epub 2016 Jun 16.

23.

The Therapeutic CD38 Monoclonal Antibody Daratumumab Induces Programmed Cell Death via Fcγ Receptor-Mediated Cross-Linking.

Overdijk MB, Jansen JH, Nederend M, Lammerts van Bueren JJ, Groen RW, Parren PW, Leusen JH, Boross P.

J Immunol. 2016 Aug 1;197(3):807-13. doi: 10.4049/jimmunol.1501351. Epub 2016 Jun 17.

24.

Neutralizing antibody affords comparable protection against vaginal and rectal simian/human immunodeficiency virus challenge in macaques.

Moldt B, Le KM, Carnathan DG, Whitney JB, Schultz N, Lewis MG, Borducchi EN, Smith KM, Mackel JJ, Sweat SL, Hodges AP, Godzik A, Parren PW, Silvestri G, Barouch DH, Burton DR.

AIDS. 2016 Jun 19;30(10):1543-51. doi: 10.1097/QAD.0000000000001102.

25.

A Novel Bispecific Antibody Targeting EGFR and cMet Is Effective against EGFR Inhibitor-Resistant Lung Tumors.

Moores SL, Chiu ML, Bushey BS, Chevalier K, Luistro L, Dorn K, Brezski RJ, Haytko P, Kelly T, Wu SJ, Martin PL, Neijssen J, Parren PW, Schuurman J, Attar RM, Laquerre S, Lorenzi MV, Anderson GM.

Cancer Res. 2016 Jul 1;76(13):3942-53. doi: 10.1158/0008-5472.CAN-15-2833. Epub 2016 May 23.

26.

Editorial overview: Special section: New concepts in antibody therapeutics: What's in store for antibody therapy?

Schuurman J, Parren PW.

Curr Opin Immunol. 2016 Jun;40:vii-xiii. doi: 10.1016/j.coi.2016.04.001. Epub 2016 Apr 12. Review. No abstract available.

PMID:
27083411
27.

Enhancing natural killer cell-mediated lysis of lymphoma cells by combining therapeutic antibodies with CD20-specific immunoligands engaging NKG2D or NKp30.

Kellner C, Günther A, Humpe A, Repp R, Klausz K, Derer S, Valerius T, Ritgen M, Brüggemann M, van de Winkel JG, Parren PW, Kneba M, Gramatzki M, Peipp M.

Oncoimmunology. 2015 Jun 5;5(1):e1058459. eCollection 2016.

28.

Monoclonal antibodies targeting CD38 in hematological malignancies and beyond.

van de Donk NW, Janmaat ML, Mutis T, Lammerts van Bueren JJ, Ahmadi T, Sasser AK, Lokhorst HM, Parren PW.

Immunol Rev. 2016 Mar;270(1):95-112. doi: 10.1111/imr.12389. Review.

29.

Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma.

Drent E, Groen RW, Noort WA, Themeli M, Lammerts van Bueren JJ, Parren PW, Kuball J, Sebestyen Z, Yuan H, de Bruijn J, van de Donk NW, Martens AC, Lokhorst HM, Mutis T.

Haematologica. 2016 May;101(5):616-25. doi: 10.3324/haematol.2015.137620. Epub 2016 Feb 8.

30.

A Novel Platform for the Potentiation of Therapeutic Antibodies Based on Antigen-Dependent Formation of IgG Hexamers at the Cell Surface.

de Jong RN, Beurskens FJ, Verploegen S, Strumane K, van Kampen MD, Voorhorst M, Horstman W, Engelberts PJ, Oostindie SC, Wang G, Heck AJ, Schuurman J, Parren PW.

PLoS Biol. 2016 Jan 6;14(1):e1002344. doi: 10.1371/journal.pbio.1002344. eCollection 2016 Jan.

31.

The INNs and outs of antibody nonproprietary names.

Jones TD, Carter PJ, Plückthun A, Vásquez M, Holgate RG, Hötzel I, Popplewell AG, Parren PW, Enzelberger M, Rademaker HJ, Clark MR, Lowe DC, Dahiyat BI, Smith V, Lambert JM, Wu H, Reilly M, Haurum JS, Dübel S, Huston JS, Schirrmann T, Janssen RA, Steegmaier M, Gross JA, Bradbury AR, Burton DR, Dimitrov DS, Chester KA, Glennie MJ, Davies J, Walker A, Martin S, McCafferty J, Baker MP.

MAbs. 2016;8(1):1-9. doi: 10.1080/19420862.2015.1114320.

32.

Real-time analysis of the detailed sequence of cellular events in mAb-mediated complement-dependent cytotoxicity of B-cell lines and of chronic lymphocytic leukemia B-cells.

Lindorfer MA, Cook EM, Tupitza JC, Zent CS, Burack R, de Jong RN, Beurskens FJ, Schuurman J, Parren PW, Taylor RP.

Mol Immunol. 2016 Feb;70:13-23. doi: 10.1016/j.molimm.2015.12.007. Epub 2015 Dec 12.

PMID:
26690706
33.

High-Throughput Screening for Internalizing Antibodies by Homogeneous Fluorescence Imaging of a pH-Activated Probe.

Riedl T, van Boxtel E, Bosch M, Parren PW, Gerritsen AF.

J Biomol Screen. 2016 Jan;21(1):12-23. doi: 10.1177/1087057115613270. Epub 2015 Oct 30.

34.

Antibody Engineering & Therapeutics 2015: The Antibody Society's annual meeting December 7-10, 2015, San Diego, CA.

Parren PW, Burton DR, Bradbury A, Huston JS, Carter PJ, Veldman T, Chester KA, Larrick JW, Alfenito MR, Scott JK, Weiner LM, Adams GP, Reichert JM.

MAbs. 2015;7(6):981-8. doi: 10.1080/19420862.2015.1089707. Epub 2015 Sep 30.

35.

Human IgG is produced in a pro-form that requires clipping of C-terminal lysines for maximal complement activation.

van den Bremer ET, Beurskens FJ, Voorhorst M, Engelberts PJ, de Jong RN, van der Boom BG, Cook EM, Lindorfer MA, Taylor RP, van Berkel PH, Parren PW.

MAbs. 2015;7(4):672-80. doi: 10.1080/19420862.2015.1046665.

36.

When blood transfusion medicine becomes complicated due to interference by monoclonal antibody therapy.

Oostendorp M, Lammerts van Bueren JJ, Doshi P, Khan I, Ahmadi T, Parren PW, van Solinge WW, De Vooght KM.

Transfusion. 2015 Jun;55(6 Pt 2):1555-62. doi: 10.1111/trf.13150. Epub 2015 May 18.

PMID:
25988285
37.

Tandem Native Mass-Spectrometry on Antibody-Drug Conjugates and Submillion Da Antibody-Antigen Protein Assemblies on an Orbitrap EMR Equipped with a High-Mass Quadrupole Mass Selector.

Dyachenko A, Wang G, Belov M, Makarov A, de Jong RN, van den Bremer ET, Parren PW, Heck AJ.

Anal Chem. 2015 Jun 16;87(12):6095-102. doi: 10.1021/acs.analchem.5b00788. Epub 2015 May 27.

PMID:
25978613
38.

Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma.

Overdijk MB, Verploegen S, Bögels M, van Egmond M, Lammerts van Bueren JJ, Mutis T, Groen RW, Breij E, Martens AC, Bleeker WK, Parren PW.

MAbs. 2015;7(2):311-21. doi: 10.1080/19420862.2015.1007813.

39.

High turnover of tissue factor enables efficient intracellular delivery of antibody-drug conjugates.

de Goeij BE, Satijn D, Freitag CM, Wubbolts R, Bleeker WK, Khasanov A, Zhu T, Chen G, Miao D, van Berkel PH, Parren PW.

Mol Cancer Ther. 2015 May;14(5):1130-40. doi: 10.1158/1535-7163.MCT-14-0798. Epub 2015 Feb 27.

40.

Complement in therapy and disease: Regulating the complement system with antibody-based therapeutics.

Melis JP, Strumane K, Ruuls SR, Beurskens FJ, Schuurman J, Parren PW.

Mol Immunol. 2015 Oct;67(2 Pt A):117-30. doi: 10.1016/j.molimm.2015.01.028. Epub 2015 Feb 17. Review.

41.

Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide.

Nijhof IS, Lammerts van Bueren JJ, van Kessel B, Andre P, Morel Y, Lokhorst HM, van de Donk NW, Parren PW, Mutis T.

Haematologica. 2015 Feb;100(2):263-8. doi: 10.3324/haematol.2014.117531. Epub 2014 Dec 15.

42.

Preclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and Bortezomib.

Nijhof IS, Groen RW, Noort WA, van Kessel B, de Jong-Korlaar R, Bakker J, van Bueren JJ, Parren PW, Lokhorst HM, van de Donk NW, Martens AC, Mutis T.

Clin Cancer Res. 2015 Jun 15;21(12):2802-10. doi: 10.1158/1078-0432.CCR-14-1813. Epub 2014 Nov 14.

43.

Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy.

Da Roit F, Engelberts PJ, Taylor RP, Breij EC, Gritti G, Rambaldi A, Introna M, Parren PW, Beurskens FJ, Golay J.

Haematologica. 2015 Jan;100(1):77-86. doi: 10.3324/haematol.2014.107011. Epub 2014 Oct 24.

44.

Controlled Fab-arm exchange for the generation of stable bispecific IgG1.

Labrijn AF, Meesters JI, Priem P, de Jong RN, van den Bremer ET, van Kampen MD, Gerritsen AF, Schuurman J, Parren PW.

Nat Protoc. 2014 Oct;9(10):2450-63. doi: 10.1038/nprot.2014.169. Epub 2014 Sep 25.

PMID:
25255089
45.

Opening the door to innovation.

Schuurman J, Graus YF, Labrijn AF, Ruuls S, Parren PW.

MAbs. 2014 Jul-Aug;6(4):812-9. doi: 10.4161/mabs.29004. Epub 2014 Apr 24. Review.

46.

Complement is activated by IgG hexamers assembled at the cell surface.

Diebolder CA, Beurskens FJ, de Jong RN, Koning RI, Strumane K, Lindorfer MA, Voorhorst M, Ugurlar D, Rosati S, Heck AJ, van de Winkel JG, Wilson IA, Koster AJ, Taylor RP, Saphire EO, Burton DR, Schuurman J, Gros P, Parren PW.

Science. 2014 Mar 14;343(6176):1260-3. doi: 10.1126/science.1248943.

47.

Antibody engineering and therapeutics, The Annual Meeting of the Antibody Society: December 8-12, 2013, Huntington Beach, CA.

Almagro JC, Gilliland GL, Breden F, Scott JK, Sok D, Pauthner M, Reichert JM, Helguera G, Andrabi R, Mabry R, Bléry M, Voss JE, Laurén J, Abuqayyas L, Barghorn S, Ben-Jacob E, Crowe JE Jr, Huston JS, Johnston SA, Krauland E, Lund-Johansen F, Marasco WA, Parren PW, Xu KY.

MAbs. 2014 May-Jun;6(3):577-618. doi: 10.4161/mabs.28421. Epub 2014 Mar 3.

48.

HER2 monoclonal antibodies that do not interfere with receptor heterodimerization-mediated signaling induce effective internalization and represent valuable components for rational antibody-drug conjugate design.

de Goeij BE, Peipp M, de Haij S, van den Brink EN, Kellner C, Riedl T, de Jong R, Vink T, Strumane K, Bleeker WK, Parren PW.

MAbs. 2014 Mar-Apr;6(2):392-402. doi: 10.4161/mabs.27705. Epub 2014 Jan 3.

49.

An antibody-drug conjugate that targets tissue factor exhibits potent therapeutic activity against a broad range of solid tumors.

Breij EC, de Goeij BE, Verploegen S, Schuurhuis DH, Amirkhosravi A, Francis J, Miller VB, Houtkamp M, Bleeker WK, Satijn D, Parren PW.

Cancer Res. 2014 Feb 15;74(4):1214-26. doi: 10.1158/0008-5472.CAN-13-2440. Epub 2013 Dec 26.

50.

Production of stable bispecific IgG1 by controlled Fab-arm exchange: scalability from bench to large-scale manufacturing by application of standard approaches.

Gramer MJ, van den Bremer ET, van Kampen MD, Kundu A, Kopfmann P, Etter E, Stinehelfer D, Long J, Lannom T, Noordergraaf EH, Gerritsen J, Labrijn AF, Schuurman J, van Berkel PH, Parren PW.

MAbs. 2013 Nov-Dec;5(6):962-73. doi: 10.4161/mabs.26233. Epub 2013 Aug 22.

Supplemental Content

Loading ...
Support Center